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Abstract
Metabolomics is a promising tool for discovery of novel biomarkers of chronic disease risk in prospective epidemiologic
studies. We investigated the between- and within-person variation of the concentrations of 163 serum metabolites over a
period of 4 months to evaluate the metabolite reliability expressed by the intraclass-correlation coefficient (ICC: the ratio of
between-person variance and total variance). The analyses were performed with the BIOCRATES AbsoluteIDQTM targeted
metabolomics technology, including acylcarnitines, amino acids, glycerophospholipids, sphingolipids and hexose in 100
healthy individuals from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study who had
provided two fasting blood samples 4 months apart. Overall, serum reliability of metabolites over a 4-month period was
good. The median ICC of the 163 metabolites was 0.57. The highest ICC was observed for hydroxysphingomyelin C14:1
(ICC = 0.85) and the lowest was found for acylcarnitine C3:1 (ICC = 0). Reliability was high for hexose (ICC = 0.76),
sphingolipids (median ICC = 0.66; range: 0.24–0.85), amino acids (median ICC = 0.58; range: 0.41–0.72) and glyceropho-
spholipids (median ICC = 0.58; range: 0.03–0.81). Among acylcarnitines, reliability of short and medium chain saturated
compounds was good to excellent (ICC range: 0.50–0.81). Serum reliability was lower for most hydroxyacylcarnitines and
monounsaturated acylcarnitines (ICC range: 0.11–0.45 and 0.00–0.63, respectively). For most of the metabolites a single
measurement may be sufficient for risk assessment in epidemiologic studies with healthy subjects.
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Introduction
The ‘‘omic’’ sciences – including genomics, proteomics and
metabolomics, among others - are promising novel approaches
that may be useful in prospective epidemiologic studies to screen
various targets at once with the aim to identify candidate
biomarkers for the estimation of the risk of chronic diseases, such
as cardiovascular disease or diabetes. Metabolomics systemati-
cally identifies and quantifies low-molecular weight compounds
that are intermediates or endpoints of metabolism. Because
metabolites may change rapidly in response to physiologic
perturbations, they may represent more proximal reporters of
intermediary or disease phenotypes than e.g. proteins [1,2,3].
Expanding the view from the more static genomic and proteomic
fields to metabolomics may, therefore, reveal more insight into a
system that is more sensitive to external stimuli. Thus,
metabolomics is a promising technique for candidate biomarker
discovery to assess chronic disease risk in large-scale epidemio-
logic studies [4]. To gain a reliable risk estimate with a single
blood measurement, as is usually obtained in large epidemiologic
studies, the within-subject variance over time should be small
compared with the between-subject variance since poor reliability
generally tends to bias relative risks in epidemiologic studies
between biomarkers and disease risk towards the null [5]. Thus,
the high sensitivity of the metabolome to internal or external
stimuli (such as age, hormonal status, diet and lifestyle) may
potentially limit their use for risk assessment in large-scale
epidemiologic studies that are based on single blood measure-
ments [6], but little is known on their within- and between-person
variance.
To address this issue, the present study aimed to evaluate the
reliability, expressed by the intraclass-correlation coefficient (ICC)
[5], as the ratio of between-person variance and total variance, of
163 targeted metabolites in fasting serum samples over a 4-month
period within a sub-sample of the European Prospective Investiga-
tion into Cancer and Nutrition (EPIC)-Potsdam cohort. This
metabolomic approach has already been successfully applied in the
human KORA cohort study [7,8], and covers acylcarnitines, amino
acids, glycerophospholipids, sphingolipids and hexoses, constituting
a biologically relevant panel of 163 metabolites.
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Results
The total sample consisted of 100 healthy participants who were
evenly distributed according to gender with a mean age of 56.1
years (Table 1). Men were older, had a higher BMI, waist-
circumference and waist-to-hip ratio than women.
Mean serum metabolite concentrations ranged from 0.01
mmol/L for a number of acylcarnitines to 5207 mmol/L for
hexose. On average, the serum reliability of 163 metabolites was
good with a median ICC of 0.57. The highest reliability was
observed for hydroxysphingomyeline SM(OH)C14:1 (ICC=0.85)
and the lowest was found for acylcarnitine C3:1 (ICC=0). The
ICCs for the individual metabolites according to their subclasses
are presented in Tables 2 to 5 (Table 2: acylcarnitines; Table 3:
amino acids, lysoglycerophospholipids, sphingolipids and hexose;
Table 4: diacyl-glycerophospholipids, and Table 5: acyl-alkyl-
glycerophospholipids). Excellent reliability (ICC$0.75) was found
for hexose; hydroxysphingomyelins SM(OH)C14:1, SM(OH)C-
22:2 and SM(OH)C16:1; sphingomyelins SMC18:1 and SMC-
16:1; phosphatidylcholines PCaeC44:6, PCaeC42:5, PCaeC36:2
and PCaeC42:4; and Butyryl-L-carnitine (C4). Among the metab-
olites that were poorly reliable (ICC,0.4), there were 16 out of 41
acylcarnitines, besides 14 out of 92 glycerophospholipids and
sphingomyelines SMC22:3, SMC20:2 and SMC26:0.
Among metabolite subclasses (Figure 1), the serum reliability was
excellent in hexose (ICC=0.76), the 15 sphingolipids showed a poor
to excellent reliability (median ICC=0.66, range: 0.24–0.85),
reliability of the 14 amino acids was fair to good with a median
ICC of 0.58 (range: 0.41–0.72) and the 92 glycerophospholipids had
a poor to excellent reliability with median ICC=0.58 (range:
0.03–0.81). The least reliable metabolite subclass included the
41 acylcarnitines with median ICC=0.45 (range: 0.00–0.81).
However, acylcarnitines were a very heterogeneous class. Among
acylcarnitines, most of the short and medium chain saturated
compounds showed a good to excellent reliability (ICC ranging from
0.50–0.81), whereas reliability of hydroxyacylcarnitines and mono-
unsaturated acylcarnitines was mostly poor to fair (ICC range: 0.11–
0.45 and 0.00–0.63, respectively). The analytical variance of the
metabolites was also evaluated measuring 230 replicates (Tables S1
and S2). 29 of the metabolites, most of them monounsaturated- and
hydroxyacylcarnitines, next to few glycerophospholipids, showed very
low serum concentrations that were below the limit of detection
(LOD) of the analytical method. After excluding these metabolites
from the ICC calculation, the overall corrected median ICCcorr was
0.59, and in specific for acylcarnitines median ICCcorr was 0.52 and
for glycerophospholipids median ICCcorr was 0.59.
Since reliability depends on both, within- and between-person
variances, we also report these variance components inTables 2 to
5, to illustrate their contribution to the ICC. For example, the
acylcarnitines C4 and C16 had very similar within-person variances
(18.7% vs. 18.8%, respectively); however, their ICCs were different
(0.49 vs. 0.81, respectively) (Table 2), which was explained by their
differing between-person variances (18.3% vs. 38.4%, respectively).
Acylcarnitine C4 showed a much lower within-person variance
compared to its between-person variance (18.8% vs. 38.4%,
respectively), leading to a high ICC (0.81) and indicating excellent
reliability; whereas acylcarnitine C16 showed similar within- and
between-person variances (18.7% vs. 18.3%, respectively), leading
to a lower ICC (0.49) and suggesting only fair reliability.
Discussion
This study, investigating the reliability of 163 serum metabolites
under fasting conditions using a commercially available kit in a
healthy sub-sample of the population-based EPIC-Potsdam cohort
over a 4-month period, observed an acceptable reliability for most
of the metabolites. Reliability was fair to excellent for hexose, all of
the amino acids, saturated short- and medium chain acylcarnitines
and most of the sphingomyelins and glycerophospholipids. The
results support the concept that these metabolites are reliable
candidates for risk assessment in prospective epidemiologic studies
with one blood sample collection, as a single measurement
appropriately reflects their long-term concentration in individuals.
Few compounds revealed higher variability, such as hydroxya-
cylcarnitines and monounsaturated acylcarnitines, which imply
restrain conditions in the design of epidemiologic studies.
A single assessment of a biochemical indicator may be
susceptible to short-term variation and not reflect true long-term
exposure. The ICC, as the ratio of between-person variance and
total variance (sum of between- and within-person variances),
reflects reliability very well as it considers both between- and
within-person variability. A high ICC can be obtained by low
within- and/or high between-person variance. A low ICC is
attributable to high within- and/or low between-person variance.
Random measurement error generally tends to decrease correla-
tion and regression coefficients in epidemiologic studies toward 0
and bias relative risks toward 1. To assess long-term exposure
using a single blood measurement, as it is often the case in large
epidemiologic studies, the between-person variance should
account for most of the observed variability in the biomarker
concentration, whereas within-person variance should be relatively
low [5,9]. This requirement was met by the majority of the
metabolites that were included in the present study.
Reliability studies often focus on technological improvement
of biochemical assays, sample handling or storage conditions
[10,11,12,13]. However, studies investigating the biological vari-
ance and over-time reliability of metabolite concentrations are
rarely found in the literature [14,15,16]. Previous studies focused on
biological variation of metabolites in other biological fluids e.g.
plasma or cerebral spinal fluid, were based on a limited number of
samples or used an untargeted metabolomics strategy. Investigators
previously reported similar high ICCs for plasma concentrations of
amino acids in different nutritional states [17]. Amino acid
metabolism is tightly regulated, and a genetic component has been
suggested to play a major role in amino acid homeostasis [17].
Therefore, intra-individual blood concentrations of amino acids are
within a narrow range. This fact is also reflected in our results, as we
found that within-person variance in amino acids is in a lower range
than between-person variance.
We found low within-person variance and excellent reliability of
hexose concentrations. Hexose includes various monosaccharides
containing 6 carbons, e.g. glucose, fructose and galactose, among
others. Hormonal control mechanisms immediately respond to
feeding, postprandial and fasting states and ensure that blood sugar
concentrations are contained within a narrow range over-time.
Table 1. Characteristics of the EPIC-Potsdam Sub-Sample.
All (n = 100) Men (n =50) Women (n=50)
Mean (SD) Mean (SD) Mean (SD)
Age (years) 56.1 (4.05) 57.9 (3.13) 54.4 (4.15)
BMI (kg/m2) 26.8 (4.04) 28.0 (3.78) 25.6 (3.96)
Waist (cm) 94.6 (13.5) 103 (10.9) 86.1 (10.1)
Waist-to-hip ratio 0.89 (0.10) 0.96 (0.06) 0.81 (0.06)
doi:10.1371/journal.pone.0021103.t001
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Table 2. Geometric Means, Variances and Intraclass-Correlation Coefficients (ICCs) of Serum Concentrations of Acylcarnitines
Measured 4 Months Apart Among 100 Healthy Subjects from the EPIC-Potsdam Cohort.
1st Measurement 2nd Measurement CV (%)
Metabolite
[mmol/L]ab Mean 95% CI Mean 95% CI P-valuec
Within-
person
Between-
person ICCd,e,,f 95% CI
C0 35.8 (34.1–37.6) 37.0 (35.3–38.8) 0.09 13.4 19.7 0.69 (0.57–0.78)
C10 0.35 (0.32–0.38) 0.37 (0.33–0.41) 0.20 27.0 38.5 0.67 (0.55–0.77)
C10:1g 0.21 (0.20–0.22) 0.23 (0.21–0.24) 0.04 20.4 23.2 0.57 (0.42–0.68)
C10:2 0.04 (0.04–0.04) 0.04 (0.04–0.04) 0.44 21.0 19.2 0.46 (0.29–0.60)
C12 g 0.13 (0.12–0.14) 0.14 (0.13–0.15) 0.09 23.1 23.0 0.50 (0.34–0.63)
C12-DCg 0.03 (0.03–0.04) 0.04 (0.03–0.04) 0.16 16.8 7.2 0.15 (0.00–0.34)
C12:1g 0.03 (0.03–0.04) 0.04 (0.03–0.04) 0.25 19.6 17.9 0.45 (0.28–0.60)
C14g 0.10 (0.09–0.10) 0.09 (0.09–0.10) 0.28 14.7 11.5 0.38 (0.20–0.53)
C14:1 0.26 (0.25–0.27) 0.27 (0.26–0.28) 0.05 15.5 16.2 0.52 (0.36–0.65)
C14:1-OHg 0.02 (0.02–0.02) 0.02 (0.02–0.02) 0.08 25.4 19.7 0.37 (0.19–0.53)
C14:2 0.04 (0.04–0.04) 0.04 (0.04–0.04) 0.39 30.7 28.4 0.46 (0.29–0.60)
C14:2-OH 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.17 37.8 20.5 0.23 (0.03–0.40)
C16 0.14 (0.13–0.14) 0.14 (0.14–0.15) 0.08 18.7 18.3 0.49 (0.33–0.63)
C16-OHg 0.01 (0.01–0.01) 0.01 (0.00–0.01) 0.20 44.8 15.4 0.11 (0.00–0.30)
C16:1g 0.05 (0.05–0.06) 0.05 (0.05–0.06) 0.99 17.6 17.1 0.49 (0.32–0.62)
C16:1-OHg 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.72 32.9 13.8 0.15 (0.00–0.34)
C16:2 0.01 (0.01–0.01) 0.01 (0.01–0.01 0.26 40.9 23.2 0.24 (0.05–0.42)
C16:2-OHg 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.02 31.6 12.4 0.13 (0.00–0.32)
C18 0.05 (0.05–0.06) 0.06 (0.05–0.06) 0.10 28.1 22.9 0.40 (0.22–0.55)
C18:1 0.18 (0.17–0.19) 0.19 (0.18–0.21) 0.00 19.2 18.7 0.49 (0.32–0.62)
C18:1-OHg 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.87 43.4 22.1 0.21 (0.01–0.39)
C18:2 0.06 (0.06–0.07) 0.07 (0.07–0.07) 0.00 21.9 23.9 0.54 (0.39–0.67)
C2 6.97 (6.55–7.41) 7.18 (6.74–7.65) 0.29 20.1 24.1 0.59 (0.45–0.70)
C3 0.39 (0.36–0.41) 0.39 (0.36–0.41) 0.97 18.7 27.9 0.69 (0.57–0.78)
C3-DC/C4-OHg 0.04 (0.04–0.04) 0.04 (0.04–0.05) 0.18 17.0 0.23 0.23 (0.04–0.41)
C3-DC-M/C5-OH 0.02 (0.02–0.02) 0.02 (0.02–0.02) 0.58 22.6 0.45 0.45 (0.28–0.59)
C3-OHg 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.08 36.7 15.6 0.15 (0.00–0.34)
C3:1g 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.27 57.6 0.00 0.00
C4 0.23 (0.21–0.25) 0.23 (0.21–0.25) 0.81 18.8 38.4 0.81 (0.73–0.87)
C4:1g 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.60 35.1 11.3 0.09 (0.00–0.28)
C4:1-DC/C6 0.09 (0.08–0.09) 0.09 (0.08–0.10) 0.13 22.0 30.6 0.66 (0.53–0.76)
C5 0.13 (0.12–0.14) 0.14 (0.13–0.15) ,.001 21.2 28.1 0.64 (0.50–0.74
C5-DC/C6-OH 0.02 (0.02–0.02) 0.02 (0.02–0.02) 0.80 25.4 0.41 0.41 (0.24–0.56)
C5-M-DCg 0.03 (0.02–0.03) 0.03 (0.03–0.03) 0.57 28.7 32.0 0.56 (0.40–0.68)
C5:1g 0.04 (0.03–0.04) 0.04 (0.03–0.04) 0.75 26.1 9.4 0.11 (0.00–0.30)
C5:1-DCg 0.01 (0.01–0.02) 0.01 (0.01–0.02) 0.68 31.8 11.3 0.11 (0.00–0.30)
C6:1g 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.57 30.1 9.8 0.10 (0.00–0.29)
C7-DC 0.04 (0.04–0.04) 0.04 (0.04–0.05) 0.26 26.1 21.7 0.41 (0.23–0.56)
C8g 0.26 (0.24–0.28) 0.28 (0.26–0.30) 0.02 20.1 33.5 0.73 (0.63–0.81)
C8:1 0.10 (0.10–0.11) 0.12 (0.11–0.13) 0.00 27.9 36.4 0.63 (0.50–0.73)
C9 0.04 (0.04–0.05) 0.04 (0.04–0.05) 0.46 26.1 30.8 0.58 (0.44–0.70)
aAbbreviations are as follows: Cx:y (x = number of carbons in the fatty acid side chain, y = number of double bonds in the fatty acid side chain), decarboxyl (DC),
hydroxyl (OH). For detailed nomenclature see Table S1.
bn = 100.
cA paired t-test based on log-transformed values was calculated to compare geometric means of metabolite concentrations over-time.
dBased on log transformed values.
eICC calculated as the ratio of between-person variance and total variance.
fFor negative values ICC was calculated based on positive variance estimators [33].
gMetabolite concentration was below the assay’s limit of detection.
doi:10.1371/journal.pone.0021103.t002
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Table 3. Geometric Means, Variances and Intraclass-Correlation Coefficients (ICCs) of Serum Concentrations of Amino Acids,
Lysoglycerophospholipids, Sphingolipids and Hexose Measured 4 Months Apart Among 100 Healthy Subjects from the EPIC-
Potsdam Cohort.
1st Measurement 2nd Measurement CV (%)
Metabolite
[mmol/L]ab Mean 95% CI Mean 95% CI P-valuec
Within-
person
Between-
person ICCd,e,f 95% CI
Amino Acids
Arg 135 (130–140) 136 (132–141) 0.49 11.4 13.7 0.59 (0.45–0.70)
Gln 726 (701–751) 741 (713–770) 0.22 11.7 14.3 0.60 (0.46–0.71)
Gly 313 (298–329) 329 (313–345) 0.01 14.1 20.4 0.68 (0.55–0.77)
His 93.7 (90.7–96.9) 96.4 (93.0–100) 0.07 11.0 13.5 0.60 (0.46–0.71)
Met 36.5 (35.1–38.0) 37.8 (36.2–39.4) 0.12 15.8 13.2 0.41 (0.24–0.56)
Orn 112 (107–118) 121 (116–127) 0.00 15.8 18.4 0.58 (0.43–0.69)
Phe 67.1 (64.6–69.7) 70.6 (68.1–73.3) 0.01 13.9 13.1 0.47 (0.30–0.61)
Pro 196 (185–208) 206 (194–219) 0.02 15.9 25.6 0.72 (0.62–0.80)
Ser 140 (134–146) 147 (141–154) 0.01 13.4 16.7 0.61 (0.47–0.72)
Thr 104 (98.7–109) 108 (103–113) 0.08 17.4 15.5 0.44 (0.27–0.59)
Trp 83.8 (81.2–86.5) 84.9 (82.2–87.8) 0.44 12.1 10.9 0.45 (0.28–0.59)
Tyr 80.1 (76.6–83.8) 84.2 (80.2–88.4) 0.03 15.9 17.4 0.54 (0.39–0.67)
Val 338 (324–353) 351 (333–369) 0.09 15.9 17.8 0.56 (0.41–0.68)
xLeu 261 (250–274) 276 (263–289) 0.01 15.7 18.1 0.57 (0.42–0.69)
Lysoglycerophospholipids
lysoPC a C14:0 3.28 (3.11–3.46) 3.36 (3.13–3.62) 0.47 24.3 21.6 0.44 (0.27–0.59)
lysoPC a C16:0 157 (151–163) 167 (160–175) 0.01 15.6 15.1 0.49 (0.32–0.62)
lysoPC a C16:1 4.51 (4.24–4.79) 4.69 (4.38–5.02) 0.20 21.7 24.8 0.57 (0.42–0.69)
lysoPC a C17:0 2.54 (2.39–2.69) 2.65 (2.49–2.82) 0.09 18.5 24.5 0.64 (0.50–0.74)
lysoPC a C18:0 49.8 (47.6–52.1) 52.6 (50.2–55.2) 0.02 16.7 16.5 0.50 (0.33–0.63)
lysoPC a C18:1 30.5 (28.9–32.1) 31.8 (30.0–33.6) 0.12 18.7 20.3 0.54 (0.39–0.66)
lysoPC a C18:2 36.33 (34.2–38.6) 37.52 (35.0–40.2) 0.29 21.2 25.1 0.58 (0.44–0.70)
lysoPC a C20:3 3.29 (3.08–3.50) 3.37 (3.18–3.58) 0.47 24.9 18.7 0.36 (0.18–0.52)
lysoPC a C20:4 8.50 (8.00-9.03) 9.11 (8.58–9.67) 0.01 19.8 23.2 0.58 (0.43–0.69)
lysoPC a C24:0g 0.37 (0.34–0.39) 0.35 (0.33–0.38) 0.32 25.2 19.3 0.37 (0.19–0.53)
lysoPC a C26:0g 0.51 (0.47–0.56) 0.51 (0.47–0.55) 0.91 31.0 32.0 0.52 (0.36–0.65)
lysoPC a C26:1g 3.09 (3.03–3.15) 3.05 (2.99–3.10) 0.28 9.1 3.7 0.14 (0.00–0.33)
lysoPC a C28:0g 0.48 (0.44–0.51) 0.47 (0.44–0.50) 0.62 24.7 24.1 0.49 (0.32–0.62)
lysoPC a C28:1 0.76 (0.71–0.81) 0.73 (0.68–0.78) 0.25 20.6 25.4 0.60 (0.46–0.71)
lysoPC a C6:0g 0.02 (0.02–0.02) 0.02 (0.02–0.02) 0.81 48.2 15.1 0.11 (0.00–0.32)
Sphingolipids
SM (OH) C14:1 7.08 (6.66–7.52) 7.18 (6.77–7.61) 0.41 11.6 27.7 0.85 (0.78–0.90)
SM (OH) C16:1 3.57 (3.37–3.78) 3.56 (3.35–3.79) 0.95 13.7 26.3 0.79 (0.70–0.85)
SM (OH) C22:1 13.7 (13.1–14.5) 13.9 (13.2–14.5) 0.69 13.7 20.7 0.70 (0.58–0.78)
SM (OH) C22:2 11.6 (10.9–12.3) 11.6 (11.0–12.3) 0.83 13.1 25.5 0.79 (0.70–0.85)
SM (OH) C24:1 1.26 (1.19–1.34) 1.22 (1.15–1.30 0.26 18.9 24.6 0.63 (0.49–0.73)
SM C16:0 125 (120–130) 127 (122–132) 0.42 11.3 15.5 0.66 (0.53–0.75)
SM C16:1 17.9 (17.0–18.7) 18.1 (17.4–19.0) 0.33 11.4 19.8 0.75 (0.65–0.83)
SM C18:0 26.4 (25.3–27.6) 26.7 (25.5–27.9) 0.60 12.8 19.0 0.69 (0.57–0.78)
SM C18:1 11.50 (10.9–12.1) 11.5 (10.9–12.1) 0.98 12.7 23.4 0.77 (0.68–0.84)
SM C20:2 0.46 (0.42–0.50) 0.44 (0.41–0.47) 0.39 32.3 19.1 0.26 (0.07–0.43)
SM C22:3 1.99 (1.81–2.19) 2.23 (2.08–2.38) 0.03 34.2 22.5 0.30 (0.11–0.47)
SM C24:0 24.0 (22.9–25.1) 24.1 (23.1–25.1) 0.78 14.2 16.3 0.57 (0.42–0.69)
SM C24:1 51.9 (49.8–54.2) 52.3 (50.0–54.6) 0.73 12.6 17.5 0.66 (0.54–0.76)
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Acylcarnitines represent esterified fatty acid derivates that
occur in the process of fatty acid translocation into the inner
mitochondrial membrane which is the limiting step for b-
oxidation. Acylcarnitines can efficiently pass into the cytosol and
subsequently into the blood stream. Blood acylcarnitine concen-
trations, therefore, reflect the substrate flux through b-oxidation.
Increased acylcarnitine concentrations have been associated with
type 2 diabetes mellitus previously [18,19]. However, information
on serum reliability is scarce. We found that short and medium
chain acylcarnitines in serum are more reliable than longer chain
hydroxy- and monounsaturated acylcarnitines. In healthy human
individuals, acylcarnitines are generally observed at low concen-
trations in plasma and serum. This might also affect the observed
ICCs and the analytical variance. Per example, all hydroxylated
acylcarnitines were below the LOD, except C14:1-OH, which
showed values very close to the LOD. Therefore, the analytical
variance observed for these metabolites is presented in Table S2.
Phosphatidylcholines belong to the group of membrane
phospholipids that consist of a glycerol core which carries a
choline head group and two fatty acid residues. Lysophosphati-
dylcholines usually originate from hydrolysis of the sn-2 fatty acid
and transesterification by phospholipase A2 and, therefore, only
carry one fatty acid. De-novo synthesis and redistribution from
plasma membranes may impact phosphatidylcholine and lyso-
phosphatidylcholine concentrations in blood [20]. Sphingomyelins
are also membrane phospholipids, but instead of glycerol, they
contain a ceramide core, including a fatty acid, and a polar head
group. Besides being part of membranes, they are also involved in
signal transduction such as nuclear factor-kB pathways [21]. This
action requires enzymatical breakdown of sphingomyelins and
release of ceramides [22]. A previous study that investigated the
reproducibility of platelet phospholipid measures in 12 subjects
over a 3-week period reported similar ICCs as observed in our
study [23]. That study found an ICC of 0.50 for total
phosphatidylcholines and an ICC of 0.54 for total sphingomyelins,
as compared to a median ICC of 0.58 for phosphatidylcholines
and median ICC of 0.66 for sphingomyelins observed in our study.
These findings indicate good reliability of most phospholipids and
support their usefulness as reliable candidate biomarkers.
The strength of our study was that we assessed reliability in a wide
spectrum of metabolites including different classes of compounds.
Furthermore, the detection assay for these metabolites represents a
modern high-throughput technique that has already been approved
and standardized, and can be applied to future metabolome
analysis. We also used a sub-sample of a large population-based
prospective cohort study for this reliability investigation, therefore,
ensuring a high precision for the results of the ICCs. The
participants of this study were free-living, and thus, their exposure
to various external factors differed reflecting a real life situation.
Our study had some limitations. The estimation of within-
person variation (% CV) was based on only two time point
measurements. This was a trade-off for the large sample size of the
present study. To account for this limitation we included a long
time span between the two measurements of metabolite concen-
trations where participants were free-living and thus, exposed to
several external factors that could have affected stability of
metabolite concentrations. The present study included fasting
healthy subjects. Reliability of metabolites may be different for
people with existing chronic disease and in situations in which
fasting status is not possible to obtain. Future studies are warranted
to further investigate the metabolite reliability in different (i.e.
those with overt disease or challenged) populations.
We were primarily interested to study the reliability of
metabolites for risk assessment using a single blood measurement,
as is usually the case in large scale epidemiologic studies. Therefore,
we did not investigate in detail possible sources of within- or
between-person variance. We are aware of a need to evaluate the
impact of genetic and non-genetic factors on these variance
components, which should be the aim of future studies. Some
metabolites, especially of the acylcarnitine group, showed lower
serum concentrations than the LOD of the assay system; thus, the
observed low ICCs could also be explained by technological
limitation. Beyond biologic variability, the total variance of the
biomarker concentrations depends on the precision of the
measurement. Although most metabolites were measured with
relatively high precision, the coefficients of variations were larger for
a few metabolites, which may explain the lower reliability for some
of these markers. Thus, the reliability depends on the assay system,
and, although we used a validated kit, the reliability of the
metabolites measured here may be different when other systems are
used. Although reliability was low for some of the metabolic markers
when analysed separately as in our analysis, this does not exclude
the possibility that these markers may still be useful when
investigating the impact of metabolic profiles on disease risk.
In conclusion, we found fair to excellent reliability for most of
the metabolites, including short- and medium chain acylcarnitines,
amino acids, hexose and phospholipids in free-living healthy
subjects. Our results suggest that a single assessment of these
1st Measurement 2nd Measurement CV (%)
Metabolite
[mmol/L]ab Mean 95% CI Mean 95% CI P-valuec
Within-
person
Between-
person ICCd,e,f 95% CI
SM C26:0 0.21 (0.20–0.22) 0.22 (0.20–0.23) 0.48 29.0 16.2 0.24 (0.04–0.41)
SM C26:1 0.46 (0.44–0.49) 0.43 (0.40–0.46) 0.04 24.4 19.8 0.40 (0.22–0.55)
Hexose 5059 (4811–5320) 5207 (4940–5488) 0.11 12.7 22.6 0.76 (0.66–0.83)
aAbbreviations are as follows: Cx:y (x = number of carbons in the fatty acid side chain, y = number of double bonds in the fatty acid side chain), hydroxyl (OH),
phosphatidylcholine (PC), acyl (a), sphingomyelin (SM). For detailed nomenclature see Table S1.
bn = 100; except: lysoPC a C6:0 n = 61; SM C20:2 and SM C22:3 n = 99.
cA paired t-test based on log-transformed values was calculated to compare geometric means of metabolite concentrations over-time.
dBased on log transformed values.
eICC calculated as the ratio of between-person variance and total variance.
fFor negative values ICC was calculated based on positive variance estimators [33].
gMetabolite concentration was below the assay’s limit of detection.
doi:10.1371/journal.pone.0021103.t003
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Table 4. Geometric Means, Variances and Intraclass-Correlation Coefficients (ICCs) of Serum Concentrations of Diacyl-
Glycerophospholipids Measured 4 Months Apart Among 100 Healthy Subjects from the EPIC-Potsdam Cohort.
1st Measurement 2nd Measurement CV (%)
Metabolite
[mmol/L]ab Mean 95% CI Mean 95% CI P-valuec
Within-
person
Between-
person ICCd,e,f 95% CI
PC aa C24:0 0.12 (0.11–0.13) 0.12 (0.11–0.13) 0.56 32.3 25.8 0.39 (0.21–0.54)
PC aa C26:0g 0.84 (0.79–0.89) 0.80 (0.77–0.84) 0.04 16.6 20.4 0.60 (0.46–0.71)
PC aa C28:1 3.55 (3.37–3.74) 3.59 (3.43–3.77) 0.51 13.4 21.3 0.72 (0.61–0.80)
PC aa C30:0 4.89 (4.62–5.18) 4.86 (4.58–5.16) 0.81 19.6 21.8 0.55 (0.40–0.67)
PC aa C30:2 0.12 (0.10–0.16) 0.13 (0.10–0.16) 0.30 96.6 51.9 0.27 (0.00–0.43)
PC aa C32:0 16.2 (15.6–16.8) 16.4 (15.8–17.1) 0.38 13.2 14.3 0.54 (0.39–0.66)
PC aa C32:1 19.3 (17.6–21.2) 19.2 (17.4–21.2) 0.88 26.4 40.3 0.70 (0.58–0.79)
PC aa C32:2 4.71 (4.39–5.05) 4.59 (4.26-4.96) 0.44 23.6 28.2 0.59 (0.44–0.70)
PC aa C32:3 0.54 (0.51–0.57) 0.55 (0.52–0.58) 0.35 16.2 21.9 0.65 (0.52–0.75)
PC aa C34:1 245 (233–259) 254 (242–267) 0.13 16.2 20.3 0.61 (0.47–0.72)
PC aa C34:2 451 (433–469) 466 (450–483) 0.07 12.6 14.1 0.55 (0.40–0.68)
PC aa C34:3 17.8 (16.9–18.9) 18.0 (16.9–19.0) 0.80 18.8 21.8 0.57 (0.43–0.69)
PC aa C34:4 2.06 (1.92–2.21) 2.06 (1.92–2.22) 0.96 22.9 27.7 0.59 (0.45–0.71)
PC aa C36:0 2.72 (2.58–2.86) 2.79 (2.64–2.94) 0.30 17.8 20.1 0.56 (0.41–0.68)
PC aa C36:1 53.1 (50.4–55.8) 53.7 (51.3–56.1) 0.61 16.1 17.7 0.55 (0.39–0.67)
PC aa C36:2 267 (256–278) 272 (262–283) 0.32 14.3 13.2 0.46 (0.29–0.60)
PC aa C36:3 142 (135–148) 144 (138–150) 0.52 15.4 15.8 0.51 (0.35–0.64)
PC aa C36:4 200 (191–211) 209 (199–220) 0.02 13.5 20.8 0.70 (0.59–0.79)
PC aa C36:5 30.6 (27.9–33.6) 29.0 (26.5–31.8) 0.21 29.9 35.4 0.58 (0.44–0.70)
PC aa C36:6 1.16 (1.07–1.24) 1.09 (1.01–1.18) 0.11 24.6 28.9 0.58 (0.43–0.70)
PC aa C38:0 2.91 (2.75–3.08) 2.93 (2.78–3.10) 0.76 16.2 22.9 0.67 (0.540.76)
PC aa C38:1 0.43 (0.34–0.55) 0.43 (0.35–0.52) 0.94 100.5 15.3 0.03 (0.00–0.23)
PC aa C38:3 53.6 (50.9–56.4) 53.5 (51.1–56.0) 0.94 16.9 17.7 0.52 (0.37–0.65)
PC aa C38:4 118 (112–125) 123 (116–130) 0.08 14.6 22.6 0.70 (0.59–0.79)
PC aa C38:5 59.0 (56.0–62.2) 58.4 (55.4–61.6) 0.65 15.9 21.4 0.64 (0.51–0.75)
PC aa C38:6 86.0 (81.2–91.0) 84.9 (80.1-90.1) 0.61 16.8 23.9 0.67 (0.55–0.77)
PC aa C40:1g 0.42 (0.40–0.44) 0.40 (0.38–0.43) 0.26 18.3 17.2 0.47 (0.30–0.61)
PC aa C40:2 0.26 (0.24–0.28) 0.25 (0.23–0.27) 0.23 35.4 14.3 0.14 (0.00–0.33)
PC aa C40:3 0.48 (0.45–0.51) 0.46 (0.44–0.49) 0.28 26.9 16.5 0.28 (0.08–0.45)
PC aa C40:4 3.74 (3.54–3.94) 3.88 (3.68–4.09) 0.14 17.7 20.4 0.57 (0.42–0.69)
PC aa C40:5 10.7 (10.1–11.3) 10.7 (10.1–11.3) 0.90 17.4 22.4 0.62 (0.49–0.73)
PC aa C40:6 31.0 (29.1–33.1) 30.4 (28.5–32.4) 0.48 19.4 25.8 0.64 (0.51–0.74)
PC aa C42:0 0.54 (0.50–0.57) 0.53 (0.50–0.57) 0.98 17.2 28.7 0.73 (0.63–0.81)
PC aa C42:1 0.25 (0.24–0.27) 0.26 (0.24–0.28) 0.59 19.8 28.1 0.67 (0.54–0.76)
PC aa C42:2 0.21 (0.20–0.22) 0.21 (0.20–0.22) 0.87 22.8 18.8 0.40 (0.23-0.56)
PC aa C42:4 0.17 (0.16–0.17) 0.17 (0.16–0.18) 0.29 24.5 11.4 0.18 (0.00–0.36)
PC aa C42:5 0.39 (0.37–0.42) 0.37 (0.35–0.39) 0.13 23.2 19.7 0.42 (0.24-0.57)
PC aa C42:6 0.65 (0.63–0.68) 0.63 (0.60–0.66) 0.09 15.2 15.7 0.52 (0.36–0.65)
aAbbreviations are as follows: Cx:y (x = number of carbons in the fatty acid side chain, y = number of double bonds in the fatty acid side chain), phosphatidylcholine
(PC), acyl-acyl (aa). For detailed nomenclature see Table S1.
bn = 100; except: PC aa C30:2 n = 73; PC aa C38:1 n = 82.
cA paired t-test based on log-transformed values was calculated to compare geometric means of metabolite concentrations over-time.
dBased on log transformed values.
eICC calculated as the ratio of between-person variance and total variance.
fFor negative values ICC was calculated based on positive variance estimators [33].
gMetabolite concentration was below the assay’s limit of detection.
doi:10.1371/journal.pone.0021103.t004
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Table 5. Geometric Means, Variances and Intraclass-Correlation Coefficients (ICCs) of Serum Concentrations of Acyl-Alkyl-
Glycerophospholipids Measured 4 Months Apart Among 100 Healthy Subjects from the EPIC-Potsdam Cohort.
1st Measurement 2nd Measurement CV (%)
Metabolite
[mmol/L]ab Mean 95% CI Mean 95% CI P-valuec
Within-
person
Between-
person ICCd,e,f 95% CI
PC ae C30:0 0.38 (0.36–0.40) 0.38 (0.36–0.41) 0.96 18.2 24.6 0.65 (0.52–0.75)
PC ae C30:1 0.25 (0.22–0.28) 0.21 (0.18–0.25) 0.12 67.9 17.7 0.06 (0.00–0.26)
PC ae C30:2 0.11 (0.11–0.12) 0.11 (0.10–0.12) 0.40 22.8 23.9 0.52 (0.37–0.65)
PC ae C32:1 3.07 (2.94–3.21) 3.10 (2.96–3.25) 0.64 13.3 18.4 0.66 (0.53–0.75)
PC ae C32:2 0.79 (0.75–0.83) 0.78 (0.75–0.82) 0.71 14.0 21.1 0.70 (0.58–0.78)
PC ae C34:0 1.55 (1.47-1.63) 1.57 (1.48–1.66) 0.70 18.0 20.9 0.57 (0.43–0.69)
PC ae C34:1 10.8 (10.4–11.3) 11.0 (10.5–11.5) 0.42 14.1 17.7 0.61 (0.47–0.72)
PC ae C34:2 12.8 (12.1–13.5) 13.2 (12.5–14.0) 0.14 17.1 22.3 0.63 (0.49–0.73)
PC ae C34:3 7.98 (7.54–8.44) 8.41 (7.93–8.91) 0.03 16.7 23.7 0.67 (0.54–0.76)
PC ae C36:0 0.68 (0.65–0.72) 0.71 (0.67–0.74) 0.18 17.4 20.1 0.57 (0.42–0.69)
PC ae C36:1 8.81 (8.40–9.23) 8.84 (8.44–9.27) 0.84 14.0 19.2 0.65 (0.53–0.75)
PC ae C36:2 14.1 (13.4–14.9) 14.1 (13.4–14.9) 1.00 13.0 23.0 0.76 (0.66–0.83)
PC ae C36:3 7.79 (7.39–8.21) 8.14 (7.74–8.55) 0.10 18.6 17.9 0.48 (0.32–0.62)
PC ae C36:4 18.8 (17.8–19.8) 19.9 (19.0–21.0) 0.02 17.8 19.4 0.54 (0.39–0.67)
PC ae C36:5 12.0 (11.3–12.6) 12.6 (11.9–13.3) 0.03 16.1 21.8 0.65 (0.52–0.75)
PC ae C38:0 1.69 (1.60–1.78) 1.66 (1.57–1.76) 0.49 17.3 21.6 0.61 (0.47–0.72)
PC ae C38:1 0.67 (0.60–0.74) 0.75 (0.69–0.82) 0.06 46.1 16.1 0.11 (0.00–0.30)
PC ae C38:2 1.48 (1.40–1.56) 1.44 (1.35–1.53) 0.38 24.5 15.7 0.29 (0.10–0.46)
PC ae C38:3 4.23 (4.03–4.45) 4.24 (4.04–4.45) 0.95 14.9 19.4 0.63 (0.50–0.73)
PC ae C38:4 13.5 (12.9–14.1) 14.0 (13.4–14.7) 0.04 13.5 18.6 0.65 (0.53–0.75)
PC ae C38:5 17.6 (16.8–18.4) 18.4 (17.6–19.2) 0.03 14.4 18.1 0.61 (0.47–0.72)
PC ae C38:6 7.82 (7.40–8.26) 7.87 (7.47–8.29) 0.76 16.2 21.6 0.64 (0.51–0.74)
PC ae C40:0g 8.62 (8.36–8.89) 8.59 (8.33–8.85) 0.80 10.3 11.5 0.56 (0.40–0.68)
PC ae C40:1 1.04 (0.98–1.09) 1.03 (0.98–1.09) 0.95 17.3 20.7 0.59 (0.44–0.70)
PC ae C40:2 2.12 (2.02–2.22) 2.11 (2.00–2.24) 0.94 14.0 22.5 0.72 (0.61–0.80)
PC ae C40:3 1.05 (1.00–1.10) 1.01 (0.96–1.06) 0.07 15.2 18.4 0.60 (0.45–0.71)
PC ae C40:4 2.11 (2.02–2.21) 2.18 (2.07–2.29 0.12 13.6 20.6 0.70 (0.58–0.79)
PC ae C40:5 3.66 (3.52–3.81) 3.71 (3.54–3.89) 0.51 14.0 17.1 0.60 (0.46–0.71)
PC ae C40:6 4.81 (4.59–5.05) 4.79 (4.55–5.05) 0.80 13.9 20.8 0.69 (0.57-0.78)
PC ae C42:0g 0.31 (0.30–0.32) 0.30 (0.29–0.32) 0.25 18.4 5.5 0.08 (0.00–0.27)
PC ae C42:1 0.36 (0.34–0.38) 0.36 (0.34–0.38) 0.93 19.0 18.7 0.49 (0.33-0.63)
PC ae C42:2 0.64 (0.61–0.67) 0.63 (0.60–0.66) 0.35 16.1 18.4 0.56 (0.42–0.68)
PC ae C42:3 0.68 (0.65–0.72) 0.65 (0.61–0.69) 0.10 18.8 22.3 0.59 (0.44–0.70)
PC ae C42:4 0.93 (0.88–0.98) 0.95 (0.90–1.01) 0.26 13.8 24.2 0.75 (0.65–0.83)
PC ae C42:5 2.10 (2.00–2.20) 2.12 (2.01–2.22) 0.66 11.7 21.5 0.77 (0.68–0.84)
PC ae C44:3 0.11 (0.10–0.12) 0.10 (0.10–0.11) 0.06 25.0 23.5 0.47 (0.30–0.61)
PC ae C44:4 0.38 (0.36–0.41) 0.40 (0.37–0.43) 0.10 18.8 29.1 0.71 (0.59–0.79)
PC ae C44:5 1.91 (1.81–2.02) 1.94 (1.83–2.06) 0.45 15.0 25.3 0.74 (0.64–0.82)
PC ae C44:6 1.27 (1.20–1.35) 1.30 (1.22–1.38) 0.38 13.3 27.3 0.81 (0.73–0.87)
aAbbreviations are as follows: Cx:y (x = number of carbons in the fatty acid side chain, y = number of double bonds in the fatty acid side chain), phosphatidylcholine
(PC), acyl-alkyl (ae). For detailed nomenclature see Table S1.
bn = 100; except: PC ae C30:1 n = 97.
cA paired t-test based on log-transformed values was calculated to compare geometric means of metabolite concentrations over-time.
dBased on log transformed values.
eICC calculated as the ratio of between-person variance and total variance.
fFor negative values ICC was calculated based on positive variance estimators [33].
gMetabolite concentration was below the assay’s limit of detection.
doi:10.1371/journal.pone.0021103.t005
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metabolites may be sufficient for risk assessment in prospective
epidemiologic studies. In contrast, reliability was lower for
monounsaturated- and hydroxyl-acylcarnitines and few glycer-
ophospholipids, which is most likely explained by their low serum
concentrations in healthy individuals that exceed the assay’s
detection limit at the present time. This may limit their use for risk
assessment when based on a single measurement.
Materials and Methods
Ethics statement
All of the EPIC-Potsdam participants gave written informed
consent and the study was approved by the ethics committee of the
medical association of the state of Brandenburg, Germany.
Study population
The EPIC-Potsdam cohort was recruited from the general
population and consists of 27,548 participants mainly aged 35–65
years at time of recruitment between 1994 and 1998 [24,25,26]. In
2007, a group of 407 EPIC-Potsdam participants were invited to
participate in a validation study of physical activity assessment
within the EPIC study, which included the collection of two blood
collections approximately 4 month apart in time. The subjects were
randomly selected among all EPIC participants who were younger
than 64 years, had a valid telephone number, had residence within a
5 km radius of the study center, and with systolic blood pressure
,180 mmHg, and diastolic blood pressure,110 mmHg at time of
recruitment. Exclusion criteria were a history of heart disease
(myocardial infarct, heart failure, cardiomyopathy, stroke or angina
pectoris), use of b–blockers, or impaired mobility, as documented in
the EPIC database at the time of the invitation. Of the 407 subjects,
11 did not respond, 176 declined participation and 12 were
excluded after a phone interview with the study physician had
revealed b-blockers medication. Thus, a total of 208 EPIC-Potsdam
subjects (83 men and 125 women) participated in the validation
study of physical activity assessment. Out of this sub-sample, a total
of 100 subjects (50 men and 50 women) were randomly selected
among those who had provided two fasting blood samples over a
period of 4 month. The first blood withdrawal was conducted
between October 2007 and March 2008 and the second blood
sample was collected between February 2008 and July 2008. Fasting
blood was drawn by qualified medical staff in a standardized
procedure using monovette tubes with coagulation activator. Serum
was fractionated by centrifugation at 2,700 xg for 10 minutes, and
stored in a freezer at 280uC until analysis.
Serum metabolite concentrations
Serum concentrations of 163 metabolites were determined
using a targeted metabolomic approach with the AbsoluteIDQTM
p150 kit (BIOCRATES Life Sciences AG, Innsbruck, Austria).
The samples were prepared according the manufacturers
protocol and the assay procedures have been described in our
previous work [27]. In short: After centrifugation, 10 mL of serum
were pipetted onto a inserted filter in a 96 well sandwich plate,
which already contained stable isotope labeled internal standards.
The filters were dried in nitrogen stream, amino acids were
derivated with 5% phenylisothiocyanate reagent (PITC) and
filters were dried again. After extraction of metabolites and
internal standards with 5 mM ammonium acetate in methanol,
the solution was centrifuged through the filter membrane and
diluted with MS running solvent. Final extracts were analyzed by
FIA-MS/MS. Detailed description of the procedure has been
described previously [27]. Metabolites were quantified by
reference to appropriate internal standards. The method was
proven to be in conformance with FDA-Guidline ‘‘Guidance for
Industry - Bioanalytical Method Validation (May 2001), which
implies proof of reproducibility within a given error range.
Measurements were performed as described in the Biocrates
user’s manual UM-P150. Analytical specifications for the LOD,
evaluated quantification ranges, further LOD for semiquantita-
tive measurements, identities of quantitative and semiquantitative
metabolites, specificity, potential interferences, linearity, precision
Figure 1. Intraclass-Correlation Coefficients (ICCs) of 163 Serum Metabolites According to Metabolite Subclass Measured 4 Months
Apart. Each data point represents the ICC of one metabolite among 100 healthy subjects from the EPIC-Potsdam cohort (n = 100; except: PC aa C30:2
n = 73; PC aa C38:1 n = 82; PC ae C30:1 n = 97; lysoPC a C6:0 n= 61; SM C20:2 and SM C22:3 n = 99). Abbreviations: AC: acylcarnitines, AA: amino acids,
GPL: glycerophospholipids, lysoGPL: lysoglycerophospholipids, SL: sphingolipids, H: hexose.
doi:10.1371/journal.pone.0021103.g001
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and accuracy, reproducibility and stability were described in
BIOCRATES manual AS-P150. The LODs were set to three
times the values of zero samples (PBS with internal standards).
The lower limit of quantification (LLOQ) and upper limit
of quantification (ULOQ) were determined experimentally by
BIOCRATES. This information is provided in Table S1. The
median analytical variance was 7.3% within-plate CV and 11.4%
between-plate CV. It was determined by measuring 230
replicates (46 plates each containing 5 replicates) of one female
serum sample and is reported in detail in Table S2. The
AbsoluteIDQTM p15 kit has previously been applied in metabo-
lomic studies in humans (7, 8,).
Metabolomic platform
The metabolomic measurements allowed simultaneous quanti-
fication of 163 metabolites including 41 acylcarnitines (Cx:y), 14
amino acids, 1 hexose, 92 glycerophospholipids (lysophosphati-
dylcholines (lysoPC), diacyl- and acyl-alkyl- phosphatidylcholines
(PC)), and 15 sphingolipids (SMx:y) in a one-step analysis.
The detailed nomenclature is provided in Table S1. Lipid side
chains were abbreviated as Cx:y, where x equaled the number of
carbons in the side chain and y denoted the number of double
bonds. The technology was limited as it could not detect the
distribution of the carbon atoms among 146 different fatty acids
and the exact position of the double bonds in complex lipids. All
glycerophospholipids were phosphatidylcholines (PC), that were
further differentiated with respect to ester (a) and ether (e) bonds,
where two letters implied that two fatty acids are bond to glycerol
(aa = diacyl, ae = acyl-alkyl), while one letter (a = acyl, e = alkyl)
and the prefix ‘lyso’ indicated the presence of a single fatty acid
residue; e.g. lysoPCaC24:0 = lysophosphatidylcholine acyl C24:0
(lignoceric acid). Sphingolipids were sphingomyelins (SM) and
hydroxysphingomyelins (SM(OH)). All acylcarnitines were natu-
rally occurring L-isomers abbreviated according to the fatty acid
that was bond (e.g. C2= acetyl-L-carnitine). DL-carnitine was
abbreviated as C0. Amino acids were presented according to
standard three letter abbreviations.
A substantial part of the metabolites determined by Absolute-
IDQTM p150 kit showed values below LOD. However, it was
important to measure those as well, as their concentrations may
increase drastically in disease or upon environmental challenge
[28,29,30]. Therefore, metabolites with a concentration lower
than the LOD (n= 29) were further reported but labeled
accordingly in the tables.
Statistical analysis
The metabolite serum concentrations were not normally
distributed as indicated by Kolmogorov-Smirnov test, but right-
skewed. Therefore, the concentrations were log-transformed and
reported as geometric means and 95% confidence intervals (CIs).
Student’s paired t-test was used to compare the concentrations of
each metabolite measured 4 month apart. Variance components
were estimated with a one-way random effects model and subject
ID as the random variable (SAS procedure: PROC ANOVA) [5].
The between- and within-person CVs (biological variance) as well
as the between- and within-plate CVs (analytical variance) were
calculated as the square root of the between- and within-person/
plate variance components from the random effects model on a
log-transformed scale [31]. To assess reliability of serum
metabolite concentrations, we calculated ICCs by dividing the
between-person variance by the total variance (sum of between-
and within-person variances), and calculated 95% CI of ICCs
[32]. For negative values, ICCs were calculated based on positive
variance estimators [33]. An ICC $0.75 was considered to
indicate excellent reliability; ICCs between 0.51 and 0.74 to
indicate good reliability; ICCs between 0.40 and 0.50 to indicate
fair reliability and an ICC ,0.40 was considered as poorly reliable
(16). All statistical analyses were performed with SAS software,
release 9.2, (SAS Institute Inc., Cary, NC). The level of statistical
significance was set at P,0.05 for two-sided testing.
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